| Therapeutics – Addressing high unmet medical needs |
Today many diseases are still incurable. In many indications, current medical treatment can only delay disease progression and/or alleviate symptoms. And it is often the case that the successful treatment of one disease is followed by subsequent medical needs arising from treatment-related side effects, reoccurrence, or chronicity.
Wellington is especially interested in financing the development of innovative therapeutic approaches addressing high unmet medical needs. These innovative therapeutics may be based on novel pathways and targets, proteins and peptides, nucleic acid-based drugs, cell-based therapies, and drug delivery technologies. By applying the highest industry standards to product development processes and defining the appropriate target indications and life cycle management strategies early on, young biotech companies and start-ups can generate enormous value and growth. Once a strong preclinical and clinical proof of concept has been demonstrated, companies can benefit from exceptional market opportunities presented by the steadily rising need of big healthcare players to add new product candidates to their pipelines.
